Several other research firms have also recently commented on BLUE. BidaskClub cut shares of bluebird bio from a sell rating to a strong sell rating in a research report on Tuesday, October 23rd. Oppenheimer restated a hold rating on shares of bluebird bio in a research report on Tuesday, November 27th. Goldman Sachs Group cut shares of bluebird bio from a conviction-buy rating to a buy rating in a research report on Friday, September 21st. Morgan Stanley decreased their target price on shares of bluebird bio from $190.00 to $186.00 and set an equal weight rating for the company in a research report on Monday, October 15th. Finally, Guggenheim started coverage on shares of bluebird bio in a research report on Monday, September 17th. They issued a neutral rating for the company. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eighteen have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $200.80.
Shares of NASDAQ:BLUE opened at $116.50 on Monday. bluebird bio has a fifty-two week low of $102.21 and a fifty-two week high of $236.17. The stock has a market cap of $6.72 billion, a P/E ratio of -15.11 and a beta of 2.37.
In other news, insider Jeffrey T. Walsh sold 1,500 shares of the stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $150.16, for a total value of $225,240.00. Following the completion of the transaction, the insider now directly owns 36,995 shares in the company, valued at $5,555,169.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Davidson sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 2nd. The shares were sold at an average price of $139.32, for a total transaction of $696,600.00. Following the completion of the transaction, the insider now owns 29,905 shares of the company’s stock, valued at $4,166,364.60. The disclosure for this sale can be found here. Insiders sold 17,600 shares of company stock valued at $2,443,947 over the last quarter. Insiders own 3.00% of the company’s stock.
Several institutional investors have recently bought and sold shares of BLUE. Stratos Wealth Partners LTD. acquired a new stake in bluebird bio during the third quarter valued at approximately $106,000. Belpointe Asset Management LLC acquired a new stake in bluebird bio during the third quarter valued at approximately $110,000. NuWave Investment Management LLC lifted its stake in bluebird bio by 10,811.1% during the third quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 973 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its stake in bluebird bio by 635.0% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock valued at $167,000 after purchasing an additional 997 shares during the last quarter. Finally, Tower Research Capital LLC TRC acquired a new stake in bluebird bio during the second quarter valued at approximately $201,000.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.